Can Sirtex turn cancer into a chronic disease?

Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package. The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside. In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.

There are no comments yet.

Please log in to write the first comment.